Janux Therapeutics has announced the dosing of its first patient in a Phase I clinical trial evaluating JANX014 for mCRPC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results